Table 1 Microbiological and clinical characteristics of CR-hvKP strains

carbapenemases genes

KPC-2

51(73.9)

22(81.5)

29(69.0)

0.250

NDM-1

6(8.7)

1(3.7)

5(11.9)

0.240

NDM-5

3(4.3)

0

3(7.10)

0.160

OXA-48

2(2.9)

1(3.7)

1(2.4)

0.790

MLST

ST11

45(65.2)

22(81.5)

23(54.8)

0.020^b

ST307

7(10.1)

0

7(16.7)

0.030^b

ST65

3(4.3)

3(11.1)

0

0.030^b

ST16

3(4.3)

2(7.4)

1(2.4)

0.310

ST967

2(2.9)

0

2(4.7)

0.250

ST37

1(1.4)

0

1(2.4)

0.420

ST15

1(1.4)

0

1(2.4)

0.420

ST782

1(1.4)

0

1(2.4)

0.420

ST219

1(1.4)

0

1(2.4)

0.420

ST340

1(1.4)

0

1(2.4)

0.420

ST883

1(1.4)

0

1(2.4)

0.420

ST656

1(1.4)

0

1(2.4)

0.420

ST2823

1(1.4)

0

1(2.4)

0.420

ST4870

1(1.4)

0

1(2.4)

0.420

Hypermucoviscosity

6(8.7)

3(11.1)

3(7.1)

0.660

KPC-2 ST11

41(59.4)

21(72.4)

20(47.6)

0.0130^b

Basic data

Age^a

58 ± 22

57 ± 14

60 ± 16

0.668

Male

54(78.3)

21(77.8)

33(78.6)

0.940

Previous Hospitalizations

40(58.0)

14(51.9)

26(67.0)

0.410

admission to ICU

49(71.0)

21(77.8)

28(66.7)

0.320

Length of stay in hospital ^a, days

32 ± 41

35 ± 44

30.5 ± 45.3

0.118

Admission temperature ^a(℃)

37.6 ± 1.1

37.9 ± 1.2

37.5 ± 1.0

0.124

Department

ICU

18(26.1)

7(25.9)

11(26.2)

0.980

Respiratory medicine

11(15.9)

5(18.5)

6(14.3)

0.640

rehabilitation medicine

12(17.4)

4(14.8)

8(19.0)

0.650

Other

28(40.6)

11(40.7)

17(40.5)

0.980

Underlying diseases

Diabetes

16(23.2)

5(18.5)

11(26.2)

0.461

Hypertension

36(52.2)

13(48.1)

23(54.8)

0.590

Cardiovascular disease

38(55.1)

17(63.0)

21(50.0)

0.290

Pulmonary disease

60(87.0)

24(88.9)

34(81.0)

0.380

Hepatobiliary and

38(55.1)

15(55.6)

23(54.8)

0.950

Pancreatic Diseases

Cerebrovascular disease

37(53.6)

16(59.3)

18(45.2)

0.103

Kidney diseases

43(62.3)

16(59.3)

27(64.3)

0.670

Hematological diseases

31(44.9)

10(37.0)

21(50.0)

0.290

Malignant tumors

10(14.5)

2(7.4)

8(19.0)

0.180

Infection type

Pneumonia

51(73.9)

21(77.8)

30(71.4)

0.560

Urinary infection

9(13.0)

1(3.7)

8(19.0)

0.051

intracranial infection

6(8.7)

5(18.5)

1(2.4)

0.020^b

Bacteremia

12(17.4)

4(14.8)

8(19.0)

0.650

Invasive procedures and devices

tracheal intubation

37(53.6)

20(74.1)

17(40.5)

0.008^b

Urinary catheter

51(73.9)

21(77.8)

30(71.4)

0.560

Central intravenous catheter

47(68.1)

21(77.8)

26(67.0)

0.170

Stomach tube

45(65.2)

20(74.1)

25(60.0)

0.210

Drainage tube

17(24.6)

6(22.2)

11(26.2)

0.710

Surgery

28(40.6)

13(48.1)

15(35.7)

0.310

Bone marrow biopsy

8(11.6)

4(14.8)

4(9.5)

0.500

Antibiotic exposure

Cephalosporins

17(24.6)

4(14.8)

13(31.0)

0.130

Carbapenem antibiotic

41(59.4)

16(59.3)

25(60.0)

0.980

β-lactam-β-lactamase

57(82.6)

23(85.2)

34(81.0)

0.650

inhibitors

Fluoroquinolones

19(27.5)

5(18.5)

14(33.3)

0.180

Aminoglycosides

10(14.5)

4(14.8)

6(14.3)

0.950

Fosfomycin

5(7.2)

1(3.7)

4(9.5)

0.360

Glycopeptides

13(18.8)

4(14.8)

9(21.4)

0.490

Chemotherapy

14(20.3)

8(29.6)

6(14.3)

0.120

Outcomes

Positive outcome

39(56.5)

17(63.0)

22(52.3)

0.390

Negative outcome

30(43.5)

10(37.0)

20(47.6)

0.390